Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2022-04-07 Interim / Quarterly Rep…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 365.6KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed quarterly financial and operational update from Genetic Technologies Limited for the quarter ended 31 March 2022. It includes specific financial figures such as revenue growth, cash receipts, cash balances, and expenses. It also discusses regulatory approvals, patent grants, product launches, commercial strategies, and outlook commentary from the CEO. The presence of substantive financial data and analysis for a quarter, along with operational highlights, aligns with the characteristics of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or press release. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-04-07 English
Change in substantial holding 5 pages 910.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of Change of Interests of Substantial Holder filed under the Corporations Act 2001. It details changes in voting power and relevant interests of The Bank of New York Mellon Corporation and its group entities in Genetic Technologies Limited. The document includes specific dates of changes, previous and present voting power, and annexures listing associated entities and detailed changes. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory notice about shareholding changes.
2022-04-03 English
GeneType Half Year Update Presentation 34 pages 3.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'GeneType Presentation Half Year Update' dated February 24, 2022. It provides an extensive overview of the company's business, market opportunity, product portfolio, innovation, global presence, and strategic focus. The content includes forward-looking statements, market size, product timelines, and operational divisions. There is no indication that this is a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript of a call or an audit report. The document is clearly a presentation aimed at investors or stakeholders to update them on the company's progress and strategy. Therefore, it fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-02-24 English
Half Year Report and Accounts 24 pages 1.0MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF YEAR REPORT' and covers the half-year ended 31 December 2021. It includes detailed financial data such as revenue, net loss, net tangible assets, and cash position. It also contains a Directors' report, auditor's independence declaration, condensed consolidated financial statements (profit or loss, balance sheet, changes in equity, cash flows), notes to the financial statements, and an independent auditor's review report. The presence of these comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a full interim report rather than a brief announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report).
2022-02-23 English
Genetic Technologies 1H FY22 results 5 pages 212.6KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX Market Announcement titled 'Genetic Technologies 1H FY22 results' dated 24 February 2022. It provides a detailed overview of the company's financial performance for the half-year ending 31 December 2021, including revenue, gross profit, operating loss, cash balance, and strategic highlights. It discusses operational and commercial developments, product launches, patent grants, and outlook commentary from the CEO. The document contains substantive financial data and analysis for a half-year period, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, but a comprehensive financial and operational update for the half-year period. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-02-23 English
US Patent Office Grants Patent for COVID-19 Risk Test 2 pages 151.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement about the granting of a US patent for a COVID-19 risk test by Genetic Technologies Limited. It contains no financial statements, no regulatory certifications, no voting results, no management changes, no earnings data, and no detailed financial or strategic presentations. The content is a corporate announcement about intellectual property and commercial opportunity, typical of a regulatory announcement to the market. The document length is 3640 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-02-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.